NZ723969A - In-situ cross-linkable polymeric compositions and methods thereof - Google Patents

Abstract

Provided is a biocompatible polymeric composition comprising 1) one or more polyanionic polymers, such as alginates or hyaluronates, and 2) one or more polycationic polymers, such as chitosan or DEAE-Dextran. The composition may be useful in the treatment of wounds as the polymers cross link in situ in a wound forming a gel. In a preferred embodiment the composition consists of 0.1 to 5% by weight of sodium alginate, 2 to 25% by weight of chitosan, and water as a solvent.

Description

PATENTS FORM NO. 5 Our ref: CLM 237497NZPR DIVISIONAL APPLICATION FILED OUT OF NZ 624233 NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION In-situ cross-linkable polymeric compositions and methods thereof We, Suneris Inc. of 180 Hardenburgh Road, Pine Bush, 12566, New York, United States of America hereby declare the ion, for which we pray that a patent may be granted to us and the method by which it is to be performed, to be particularly described in and by the ing statement: (Followed by page 1a) 103923515_1.docx:JX:ewa IN-SITU CROSS-LINKABLE POLYMERIC COMPOSITIONS AND METHODS THEREOF This application claims the benefit of provisional patent application Ser. No. 61/559,110, filed 13 November 2011, the entire disclosure of which is incorporated herein by reference.

FIELD OF THE INVENTION The present invention s generally to a composition using a biocompatible polymeric formulation and, in particular, to a hemophilic polymeric matrix for use in wound healing, blood coagulation, and cosmetic use.

BACKGROUND OF THE INVENTION Wound healing is an intricate, orchestrated process involving the ctions of various cells and matrix components to first establish a provisional tissue and then remodel this while forming the mature replacement. lly, the hemostatic platelet plug reestablishes the infection-limiting and desiccation-limiting barrier, and s the first wave of cellular infiltrates. This consists mainly of leukocytes that provide both innate and ed immunity. These cells produce s and al molecules to eliminate ial contamination; however, these same defense mechanisms are detrimental to the keratinocytes, lasts and endothelial cells required to regenerate the lost tissue. Thus, as healing proceeds, the events and processes of the inflammatory phase need to s.

A particular challenge is offered in the case of skin wound repair, which occurs at a contaminated surface. If a wound s infected, the normal healing is disrupted as the inflammatory phase becomes chronic, suppressing the regenerative phase. Further, the enzymes liberated by both the microbes and leukocytes break down the wound tissue as well as surrounding skin. Thus, it is critical to ensure proper g to prevent infections being established by normal skin wound contaminants.

Wound healing is usually divided into three phases: the inflammatory phase, the proliferative phase, and the remodeling phase. Fibronectin has been reported to be involved in each stage of the wound healing process, particularly by ng a scaffold to which the ng cells will adhere. Initially, there is a release of many mediators to the wound site, such as fibronectin and fibrinogen. Fibronectin promotes inflammatory cell migration into the wound and debris phagocytosis by monocytes. Thereafter, angiogenesis and (Followed by page 2) reepithelialization take place. At this stage, fibronectin exerts actic activity on endothelial cells, and promotes epithelial cell and fibroblast migration onto the basal ne. Fibronectin also appears to be ial in the remodeling phase where it plays a major role in the organization of collagen fibrils. The lar collagen ultimately forms fibrous bundles that enhance the tissue tensile strength, leading to would closure.

Hydrogels have typically been utilized as topical formulations for promoting the wound healing process. The gel compositions have been selected for their properties of swelling , biocompatibility, permeability, and ng kinetics. Examples of such compounds have included vinyl polymers (e.g. polyacrylic acid), cellulose, and cellulose derivatives. Polyacrylic acid polymer, also referred to as carbomer, has been used because of its superiority in delivering fibronectin to skin wounds.

Naturally occurring ymers have applications in tissue engineering, regenerative ne, drug delivery, medical implant, plastic surgery, and others. Such products have ents including onic acid (HA), chitosan, heparin, oitin sulfate, alginate and other amine and glycosaminoglycans, other polysaccharides, and derivatives thereof.

In combination, concentrations of fibronectin (and similar proteins) have been utilized with alginate salt to treat chronic ulcers. The dressing system has been solidified, converting the gel into fibers, by a process of freeze-drying. This procedure creates a sponge-like structure with hydrophilic properties. In the presence of fluids, the dressings can return to a gel-like state, absorbing up to 20 times their weight in wound exudate. The dressing is easily d after the wound treatment because of its sponge-like structure and moisture retention. However, once hydrated with saline solution, the fibronectin-cellulose dressing does not provide the d fibrous protective film on the surface of the deepithelialized human skin. Debridement is then performed upon removal of the ng to remove any necrotic material.

Thus, problems exist in the treatment of acute and chronic wounds, including delayed g, reduced granulation and epithelialization, and persistent wound inflammation.

Compromised wound healing can result in other complications and problems, such as infection, pain, and development of chronic (non-healing) wounds.

Current needs exist in the treatment of chronic wounds which would assist healing, decrease inflammation, reduce pain, and prevent scar formation with both acute and chronic wounds. Such acute wounds that could be treated e burns, abrasions, dry skin, post-op surgical incisions, cuts, puncture wounds, blisters, insect bites, and other severe tissue injury.

Chronic wound ent might ass slow to heal wounds including pressure ulcers, venous ulcers, diabetic foot ulcers, decubitus ulcers, and non-healing tissue injuries.

Overall, a composition is desired that will be easily applied, forming a matrix conducive to the healing of a , and having anti-microbial properties. The composition may be biocompatible or quickly d to avoid possibilities of xicity. Further, the composition will stimulate and maximize wound healing while providing a controlled method for ing thin and thick layers of a fied wound dressing, as desired.

Indirect effects may include reduced need for medical procedures such as debridement, decreased hospitalization time, d postoperative recovery times, shortened return interval to daily functions and work, and reduced overall treatment costs. Desirably, these improvements to wound healing, including application and method of use, will be le in treating and repairing various tissue(s).

SUMMARY OF THE ION The following invention is a biocompatible polymeric composition that is a gelatinous wound healing and hemostatic matrix able to be formed and fied both internally and externally.

In one embodiment of the invention, the biocompatible polymeric composition comprises 1) one or more than one polyanionic polymer and 2) one or more than one polycationic polymer. In one embodiment of the invention, the one or more than one polyanionic polymer includes at least one cross-linkable polyanionic polymer. In another embodiment of the invention, the one or more than one polyanionic polymer includes at least one cross-linkable polyanionic polymer and at least one oss-linkable polyanionic polymer.

In one embodiment of the invention, the biocompatible polymeric composition ses a mixture of 1) one or more than one polyanionic polymer able to be formed on the surface of a wound and 2) one or more than one polycationic polymer that assists in the solidification process as well as speeds up blood clotting. In another embodiment of the invention, the biocompatible polymeric composition comprises a mixture of 1) one or more than one polyanionic polymer able to be formed on the surface of a wound; 2) one or more than one polycationic polymer that assists in the solidification process as well as speeds up blood clotting; and 3) a cross-linking mist that links the gel in the wound while disinfecting the nding area.

In one embodiment of the invention, the one or more than one polyanionic polymer comprises alginates or hyaluronates. In one embodiment of the invention, the one or more than one polycationic polymer comprises chitosan. In one embodiment of the invention, the cross-linking mist may be aqueous calcium chloride.

One or more methods of using the medical gel of the invention are also disclosed, including rapidly achieving hemostasis without the need to apply pressure, and providing a biocompatible wound g matrix.

Various ments of the invention allow the formulation to be ed and implemented for varying the desired ity and pre-determined characteristic functions. In one aspect, the ratio of the polycationic polymer to the polyanionic polymer may be improved, having varying s of ency in wound healing. In another aspect, therapeutics can be added to integrate drug formulations for drug delivery options. Further, other features may encompass controlling temperature(s) and/or pressure(s) during the preparation of the medical gel, during application of the gel, and implementing a l for the elasticity or rigidity of the solidified matrix. The matrix formulation, both liquid and solidified structures, may also be dependent on anatomical and physiological measurements and ions.

Various embodiments of the invention allow the composition to be adjusted and implemented at a first tissue site or a second tissue site, and such modification deemed obvious may be integrated and combined in varying quantities to provide for a structural matrix of any size, shape, and configuration.

DESCRIPTION OF THE DRAWINGS is a side view of an embodiment of the present invention. is a microscopic depiction of how the t invention interacts with blood and itself.

FIGS. 3A to 3I show various polymeric subunits that can be used to make up the tionic or polyanionic polymers. shows the benefits of the present invention as compared to existing technology.

DETAILED DESCRIPTION OF THE INVENTION In the following detailed ption, for purposes of ation and not limitation, exemplary embodiments disclosing specific details are set forth in order to provide a thorough understanding of the present invention. However, it will be apparent to one having ry skill in the art that the present invention may be practiced in other embodiments that depart from the specific details disclosed herein. In other instances, detailed descriptions of nown compositions and methods may be omitted so as not to obscure the description of the present invention.

Biocompatible polymeric compositions of the present ion may be used to treat external wounds as well as internal wounds. In one embodiment of the invention, the biocompatible polymeric composition may be d to a variety of wounds. Non-limiting examples of wounds include, but are not limited to: an external laceration, an abrasion, a burn, an ocular laceration, damage to a parenchymal organ, an internal laceration, a laceration in the gastrointestinal tract, superficial cuts and scrapes, internal bleeding, an arterial bleed, a venous bleed, dental or oral bleeds and ons. Subjects who can benefit from such wound ent include a variety of s including humans, mammals such as horses, sheep, cattle, hogs, dogs, cats, and marine animals such as whales, dolphins, seals, otters, fish, and reptiles such as turtles.

An illustration of a structural matrix in accordance with one embodiment of the invention is shown in As depicted, a damaged section of tissue, wound (112) , has vasculature (116) protruding throughout. A biocompatible polymeric composition (114) has been applied to the wound (112), which has been coated with protective coat (110) . shows a magnified view of one ment of biocompatible polymeric composition (114), which comprises structural polymer (226 ) and hemophilic polymer (224) .

Structural polymer (226 ) comprises about 0.1% to 95% by total composition weight of a linkable polyanionic polymer and 0% to 95% by total composition weight of a noncross-linkable polyanionic polymer. Hemophilic polymer (224 ) comprises about 1% to 90% by total composition weight of a polycationic polymer. Red blood cell (210 ) is shown in relation to the cationic on groups (212 ) via a red blood cell-cationic group linkage (216 ).

FIGS. 3A to 3I show various polymers that can be chosen as structural polymer (226) or hemophilic polymer (224) . Polymers can be modified through the addition of ymethyl (CM) groups to gain anionic functional groups (218 ). shows carboxymethyl cellulose. Alginate (3A ), sodium hyaluronate (3F ), κ-carrageenan (3G ), ιcarrageenan (3H ), and sodium polyacrylate (3I ) are examples of polymers that would function as ural polymer (226 ). Likewise, chitin (3B ) and an (3C ) are examples of polymers that would function as hemophilic polymer ( 224 ). shows how any polymer (340) can be modified with a diethylaminoethyl (DEAE) group to gain ic functional groups (212 ).

Biocompatible polymeric composition (114 ) contains about 0.1% to 99.8% by total ition weight of a solvent. In one embodiment of the invention, the solvent is l.

Preferably the solvent is a 5% aqueous on of ethanol in water. Non-limiting examples of solvents include water, ethanol, amyl acetate, e, methyl ethyl ketone, isopropanol, and tetrahydrofuran. In solution, structural polymer (226 ) and hemophilic polymer (224 ) experience intermolecular interactions which bind them together. Cationic function groups (212 ) on hemophilic polymer (224 ) attract anionic functional groups (218 ) on structural polymer (226 ) and result in ionic cross-linking (214 ). Additionally, hemophilic polymer (224 ) and ural polymer (226 ) can be covalently cross-linked (228 ), similar to a Schiff base or azomethine linkage.

Protective coat (110 ) comprises 0.1% to 30% by weight of a di- or higher valent cation (220 ), 0% to 90% by weight of a hydrophobic polymer, and 5% to 99.9% by weight of a solvent. Protective coat (110 ) cross-links composition (114) by diffusing divalent cation (220 ) inwards, which results in divalent cation cross-linking (222 ) of ural polymer (226 ). This increases the rigidity of composition (114 ) and allows for better stability.

Protective coat (110 ) can also contain hydrophobic polymers, which limit the water loss from composition (114 ) and improve lity. The hydrophobic polymer may be a ethane, nitrocellulose, a crylate, a styrene, a trafluoroethane, and a silicone, and combinations thereof. The solvent may be water, amyl acetate, acetone, methyl ethyl ketone, panol, and tetrahydrofuran, and combinations thereof. The di- or higher valent cation may be Ca2+, Fe2+, Fe3+, Ag2+, Ag3+, Au2+, Au3+, Mg2+, Cu2+, Cu3+, and Zn2+. In one embodiment of the invention, the cation is Ca2+.

In one embodiment of the invention, structural polymer (226 ) comprises 0.1% to 5% by weight of sodium alginate and 1% to 5% by weight of sodium hyaluronate, hemophilic polymer (224 ) comprises 2% to 25% by weight of chitosan chloride, and the solvent comprises 65% to 96.9% by weight of a 5% aqueous solution of ethanol in water. In this embodiment, the composition functions as a wound healing matrix to facilitate faster tissue regeneration.

In another embodiment, structural polymer (226 ) comprises 2% to 5% by weight of sodium alginate and 0% to 2% by weight of sodium hyaluronate, hemophilic polymer (224 ) comprises 5% to 20% by weight of chitosan chloride, and the solvent ses 73% to 93% by weight of a 5% aqueous solution of ethanol in water. In this embodiment, the composition functions as a thick gel for rapidly achieving hemostasis without the need to apply pressure.

The composition can be red topically to the compromised blood vessel.

In another embodiment of the invention, structural polymer (226 ) comprises 0.1% to 4% by weight of sodium alginate and 1% to 5% by weight of a lysine-rich polypeptide, hemophilic polymer (224 ) ses 5% to 25% by weight of diethylaminoethyl-dextran (DEAE-Dextran), and the solvent comprises 65% to 93% by weight of a 5% s solution of ethanol in water. The biocompatible polymeric composite (114 ) is then cross-linked in situ by applying an aerosol mist comprising 0.1% to 1% by weight of m chloride, 1% to 5% by weight of nitrocellulose, and 94% to 98.9% by weight of amyl acetate. In this embodiment, the composition ons as a protective covering for cuts and scrapes that is e and limits water loss from the wound.

In one embodiment of the invention, the biocompatible polymeric composition ses about 3.6% by weight of sodium alginate, about 7% by weight of an chloride, and about 89.4% by weight of a 5% aqueous on of ethanol in water. This embodiment may function as a composition to treat arterial bleeds.

In one embodiment of the invention, the protective coat comprises a solution comprising about 0.1% to about 30% by weight of a di- or higher valent cation; 0% to about 90% by weight of a hydrophobic polymer; and about 5% to about 99.9% by weight of a solvent. In one embodiment of the invention, the protective coat comprises a solution comprising about 0.1% to about 1% by weight of a di-valent cation; about 1 to about 5% by weight of a hydrophobic polymer; and about 94% to about 98.9% by weight of a solvent.

In one embodiment of the invention, composition (114 ) is used as a carrier for a therapeutic agent such as a drug or biologic le. The use of composition (114) as a drug delivery system improves the efficiency of the wound healing gel. In one aspect, protective coat (110 ) is prepared with a salt of silver, increasing the antimicrobial properties of the gel.

In one embodiment, the therapeutic agent is selected from the group consisting of: antimicrobial agents, antibiotics, hormones, proteins (such as calreticulin, thrombin, prothrombin, Factor VIII), and iodine, and ations thereof. In one embodiment of the ion, the therapeutic agent is preferably iodine. In r embodiment of the invention, the therapeutic agent is a protein.

In one embodiment of the invention, the cross-linkable polyanionic polymer may be a polystyrene sulfonate (such as sodium polystyrene sulfonate), a polyacrylate (such as sodium polyacrylate), a polymethacrylate (such as sodium thacrylate), a polyvinyl sulphate (such as sodium polyvinyl sulphate), a polyphosphate (such as sodium polyphosphate), Iota carrageenan, Kappa carrageenan, gellan gum, carboxyl methyl cellulose, yl methyl agarose, carboxyl methyl dextran, carboxyl methyl chitin, carboxyl methyl an, a polymer modified with a carboxyl methyl group, an alginate (such as sodium alginate), a polymer containing a plurality of carboxylate groups, a xanthan gum, and combinations thereof. Preferably, the crosslinkable polyanionic r is an alginate, more preferably sodium alginate.

Preferably the cross-linkable ionic polymer ses about 1% to about 95% by weight of the biocompatible polymeric composition; preferably the cross-linkable polyanionic polymer ses about 5% to about 40% by weight of the biocompatible polymeric composition; preferably the linkable polyanionic polymer comprises about % to about 30% by weight of the biocompatible polymeric composition.

In one embodiment of the invention, the non-cross-linkable polyanionic polymer may be a hyaluronate (such as sodium onate), a polynucleotide (such as RNA), a polypeptide chain having an average residue isoelectric point below 7, a glucosaminoglycan, and a proteoglycan, and combinations thereof. Preferably the non-cross-linkable ionic polymer is a hyaluronate, more preferably sodium hyaluronate.

Preferably the non-cross-linkable polyanionic polymer comprises about 0 to about 95% by weight of the patible polymeric composition; preferably the non-crosslinkable polyanionic polymer comprises about 5 to about 25% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable polyanionic polymer comprises about 0 to about 5% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable polyanionic polymer comprises about 0 to about 2% by weight of the biocompatible polymeric composition; preferably the non-cross-linkable ionic polymer comprises about 1 to about 5% by weight of the biocompatible polymeric ition.

In one embodiment of the ion, the polycationic polymer may be a chitosan (such as chitosan chloride), chitin, diethylaminoethyl-dextran, diethylaminoethyl-cellulose, diethylaminoethyl-agarose, diethylaminoethyl-alginate, a polymer modified with a diethylaminoethyl group, a r containing a plurality of protonated amino groups, and a polypeptide having an average residue isoelectric point above 7, and ations thereof.

Preferably the polycationic polymer is a chitosan, more preferably chitosan chloride.

Preferably the polycationic polymer is diethylaminoethyl-dextran (DEAE-Dextran).

Preferably the polycationic polymer comprises about 1% to about 90% by weight of the biocompatible polymeric ition; preferably the polycationic polymer comprises about 2% to about 80% by weight of the biocompatible polymeric composition; preferably the polycationic polymer comprises about 2% to about 25% by weight of the biocompatible polymeric composition.

The individual components of the biocompatible polymeric composition may be stored in a variety of different containers for a variety of different applications, including for example, packets, sachets, tubes, tubs, pumps, syringes, bottles, bags, and aerosol-based spray cans. The components may be stored in containers made of a variety of materials, including for example, c, metal, or glass. The components may be provided in operably connected configurations, or as separate components for a user to set up prior to use.

The compositions and systems described herein may be included in a kit or article of manufacture for forming a patible ric composition comprising one or more of: a solution comprising a polyanionic polymer; a solution comprising a polycationic polymer; a solvent; and a solution comprising a di- or higher valent cation, a hydrophobic polymer, and solvent. The kit or article of manufacture may further contain gauze, bandages, tape, brushes, spatulas, and sponges.

A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of this document. In particular, for example, various compositions of the solutions have been described, but g similar ents and elements may be integrated or utilized in substitution to achieve the same or similar effect. er, varying matrices may be employed to target diverse wound locations, internal or external to the dermal layers of the skin, including organ lantation, tissue grafting, and/or various al incisions and lesions at any site or location external and/or internal to the body. Accordingly, other implementations are within the scope of the following claims. r, the studies bed may utilize one embodiment of the composition to form a rigid matrix while another composition may be designed with an increased elasticity, alone or in ation. Further, the methods of mixing and ating the ition may be med in any order and combination so as to achieve the same or similar effects of the embedded solidified , the matrix integrating the formation of naturally restructuring tissue. In one embodiment, the one or more than one polyanionic polymer is first applied to a wound and then the one or more than one polycationic polymer is applied to the said one or more than one polymeric polymer at the wound site. In one embodiment, the one or more than one polyanionic polymer is mixed with the one or more than one polycationic polymer and then the mixture is then applied to the wound. In one embodiment, the one or more than one polyanionic polymer is d to a wound at the same time, or about the same time, that the one or more than one polycationic polymer is applied to a wound.

In one embodiment, a method of treating a wound comprises applying one or more than one ionic polymer to a wound and then applying one or more than one polycationic polymer to the said one or more than one polymeric polymer at the wound site.

In one embodiment, a method of ng a wound comprises mixing one or more than one polyanionic polymer with one or more than one polycationic polymer and then applying the mixture to the wound. In one embodiment, a method of treating a wound comprises applying one or more than one polyanionic polymer to the wound at the same time, or about the same time, as one or more than one tionic polymer is applied to a wound.

Claims (14)

What is claimed:

1. A composition consisting of: a) 0.1 % to 5% by weight of sodium alginate; b) 2% to 25% by weight of chitosan; and c) water as a solvent.

2. The composition of claim 1, consisting of 2% to 5% by weight of sodium alginate.

3. The composition of claim 1 or claim 2, consisting of 73% to 93% by weight of water.

4. Use of a composition consisting of: a) 0.1 % to 5% by weight of sodium alginate; b) 2% to 25% by weight of chitosan; and c) water as a solvent, in the preparation of a medicament for ng a bleed.

5. The use of claim 4, wherein the ition consists of 2% to 5% by weight of sodium alginate.

6. The use of claim 4 or claim 5, n the composition consists of 73% to 93% by weight of water.

7. The use of any one of claims 4 to 6, wherein the bleed is an arterial bleed, a venous bleed, a dental bleed or an oral bleed.

8. The use of claim 7, wherein the bleed is an arterial bleed.

9. The use of claim 7, wherein the bleed is a venous bleed.

10. The use of any one of claims 4 to 9, wherein the medicament is adapted to treat the bleed t the need to apply pressure.

11. The use of any one of claims 4 to 10, wherein the medicament is adapted to form a hemostatic matrix at a bleed site.

12. The use of any one of claims 4 to 10, wherein the medicament is adapted to solidify at a bleed site.

13. The composition of claim 1, substantially as herein described with reference to any one of the s thereof.

14. The use of claim 4, substantially as herein described with reference to any one of the Examples and/or